MCL Literature Feed

In real-world relapsed/refractory MCL, ibrutinib dose reduction to manage toxicity is common and does not compromise response rates, PFS, or OS, validating this as a practical clinical strategy.

In a large real-world analysis, R-CHOP/R-DHAP trended toward better OS in transplant-eligible patients, while rituximab maintenance, not initial chemo, drove survival in transplant-ineligible patients.

An expert panel opinion advocates for personalized MCL therapy, positioning BTKi as a frontline standard for transplant-ineligible patients and a potential alternative to consolidation transplant for others.

Zanubrutinib plus age-adapted bendamustine-rituximab induction followed by zanubrutinib maintenance demonstrates high efficacy (75% 2-year PFS) and deep responses (94% uMRD) in elderly, frontline MCL patients.

A case of CD5+ cutaneous DLBCL highlights a diagnostic pitfall, as it can mimic MCL but is distinguished by cyclin D1 negativity, reinforcing the need for complete immunohistochemical workup.

In a large real-world cohort, brexu-cel demonstrated high efficacy in R/R MCL patients ≥70 years, indicating functional status, not chronological age, should determine CAR-T eligibility.

A case report demonstrates repeated MCL progression upon initiation of the JAK-1 inhibitor upadacitinib for psoriatic arthritis, suggesting a potential role for JAK signaling in promoting MCL growth.

This case report details pleomorphic MCL presenting as life-threatening hemophagocytic lymphohistiocytosis (HLH), emphasizing the need for high clinical suspicion of this rare, sepsis-mimicking oncologic emergency.

This case report identifies fingertip fissures as a rare dermatologic toxicity of ibrutinib in an elderly MCL patient, expanding the known adverse event profile for this common therapy.

Population-level data confirms rituximab maintenance improves overall survival after R-CHOP induction, with a notable benefit for patients achieving only a partial response.

The combination of acalabrutinib with bendamustine-rituximab is evaluated as a frontline therapy for elderly MCL patients, aiming to improve outcomes over standard chemoimmunotherapy.

This case report details a rare MCL-induced paraneoplastic 'full-house' nephropathy mimicking lupus nephritis, which resolved with lymphoma-directed therapy, expanding the spectrum of known renal complications.

A new genomic model integrating mutations (e.g., TP53) and copy number variations improves risk stratification for elderly, newly diagnosed MCL patients treated with chemoimmunotherapy.

This multi-center study provides real-world data on treatment outcomes for elderly mantle cell lymphoma patients, offering crucial insights for managing this common and clinically challenging population.

This case report links the next-generation BTKi orelabrutinib to multiple skin cancers, suggesting this toxicity may be a class effect and reinforcing the need for dermatologic surveillance.

Real-world data from older Chinese MCL patients shows BTKi-based regimens and maintenance therapy significantly improve survival, validating these strategies for this specific, understudied elderly population.

Radiotherapy for localized orbital MCL achieves excellent long-term cancer-specific survival (83% at 15 years), supporting its use as a primary treatment, especially for elderly or frail patients.

This first reported case of mantle cell lymphoma with hypereosinophilia demonstrates a rare paraneoplastic presentation where eosinophil counts normalized following successful immunochemotherapy, expanding the disease's clinical spectrum.

In the frontline MANTLE-FIRST study, fitness status and time to first progression (PFS1) were identified as key prognostic factors for elderly MCL patients, impacting subsequent outcomes.

This case report of mantle cell lymphoma presenting solely as a cutaneous nodule in an elderly patient underscores the need to consider lymphoma in atypical skin lesions for accurate diagnosis.

This first-of-its-kind case report documents mantle cell lymphoma presenting as appendiceal intussusception, highlighting a rare gastrointestinal manifestation to consider in elderly patients with this surgical emergency.

A pooled analysis of six phase 3 trials shows median overall survival for young, fit MCL patients improved from 4.9 years to not reached, driven by intensified frontline chemoimmunotherapy and transplant.

Frontline ibrutinib-rituximab improves progression-free survival over immunochemotherapy in older MCL patients, establishing a new chemotherapy-free standard of care option.

This review provides a framework for selecting frontline therapies for older MCL patients, weighing less-intensive chemoimmunotherapy against novel agents like BTK inhibitors based on patient-specific factors.

This SHINE trial analysis shows ibrutinib's PFS benefit with BR is consistent across exposure levels, supporting dose reductions for toxicities like atrial fibrillation without compromising efficacy.

A 2022 real-world Japanese study shows chemotherapy remains dominant frontline while BTKis are common second-line, with physicians prioritizing quality of life for BTKi-treated patients over tumor response.

Adding venetoclax to RBAC chemo-immunotherapy improves 2-year progression-free survival to 60% for older, high-risk MCL patients, validating a new risk-stratified, fixed-duration frontline treatment.

The EHA-EU MCL network published comprehensive guidelines standardizing risk-stratified diagnosis and treatment for MCL, covering young/fit and elderly patients in both frontline and relapsed/refractory settings.

This review argues that new agents like BTKi are disrupting the frontline MCL standard of care, challenging ASCT's role and demanding personalized, risk-adapted treatment guidelines to resolve clinical uncertainty.

A rare case of composite CLL/MCL highlights diagnostic challenges from overlapping immunophenotypes, reinforcing the critical need for molecular and cytogenetic studies like FISH for t(11;14) for definitive diagnosis.